OLD National Bancorp IN Has $3.85 Million Stake in Quest Diagnostics Incorporated $DGX

OLD National Bancorp IN trimmed its stake in Quest Diagnostics Incorporated (NYSE:DGX) by 12.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,168 shares of the medical research company’s stock after selling 3,181 shares during the period. OLD National Bancorp IN’s holdings in Quest Diagnostics were worth $3,847,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. State Street Corp grew its position in Quest Diagnostics by 0.8% in the 3rd quarter. State Street Corp now owns 5,223,930 shares of the medical research company’s stock worth $995,577,000 after purchasing an additional 38,931 shares during the last quarter. Boston Partners lifted its holdings in shares of Quest Diagnostics by 32.8% during the 3rd quarter. Boston Partners now owns 4,036,881 shares of the medical research company’s stock worth $767,978,000 after acquiring an additional 997,033 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Quest Diagnostics by 0.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,907,510 shares of the medical research company’s stock worth $363,509,000 after acquiring an additional 6,155 shares during the period. Invesco Ltd. lifted its holdings in shares of Quest Diagnostics by 1.8% during the 3rd quarter. Invesco Ltd. now owns 1,688,769 shares of the medical research company’s stock worth $321,846,000 after acquiring an additional 30,418 shares during the period. Finally, Bank of America Corp DE lifted its holdings in shares of Quest Diagnostics by 2.2% during the 3rd quarter. Bank of America Corp DE now owns 1,635,075 shares of the medical research company’s stock worth $311,613,000 after acquiring an additional 35,473 shares during the period. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, SVP Patrick Plewman sold 5,662 shares of Quest Diagnostics stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $204.00, for a total transaction of $1,155,048.00. Following the completion of the transaction, the senior vice president directly owned 15,381 shares of the company’s stock, valued at $3,137,724. This trade represents a 26.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Michael E. Prevoznik sold 3,878 shares of Quest Diagnostics stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $206.21, for a total transaction of $799,682.38. Following the transaction, the senior vice president directly owned 37,557 shares of the company’s stock, valued at $7,744,628.97. This represents a 9.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 24,083 shares of company stock valued at $4,945,262. Company insiders own 8.16% of the company’s stock.

Analyst Ratings Changes

DGX has been the subject of a number of analyst reports. UBS Group raised their price objective on shares of Quest Diagnostics from $210.00 to $220.00 and gave the stock a “neutral” rating in a report on Wednesday. Wall Street Zen downgraded shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Sunday, March 15th. Truist Financial raised their price objective on shares of Quest Diagnostics from $220.00 to $225.00 and gave the stock a “hold” rating in a report on Wednesday. Robert W. Baird raised their price objective on shares of Quest Diagnostics from $224.00 to $229.00 and gave the stock a “neutral” rating in a report on Wednesday. Finally, Mizuho raised their price objective on shares of Quest Diagnostics from $210.00 to $235.00 and gave the stock an “outperform” rating in a report on Thursday, February 12th. Seven investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Quest Diagnostics presently has a consensus rating of “Hold” and a consensus target price of $214.54.

Trending Headlines about Quest Diagnostics

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Q1 beat and raised FY‑2026 outlook — Quest reported stronger-than-expected Q1 revenue and EPS and raised its 2026 guidance, with the CEO citing broad‑based growth across consumer testing and advanced diagnostics. That fundamental beat is the primary bullish catalyst. Quest Diagnostics raises 2026 forecast, CEO highlights broad‑based growth
• Positive Sentiment: Analysts raised estimates and price targets after Q1 — Several firms lifted forecasts/targets (UBS, Robert W. Baird, Barclays, Truist) and coverage pieces highlighted upgraded revenue/earnings outlooks, supporting upside to consensus. These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Earnings
• Positive Sentiment: Technical/market‑strength signal — IBD upgraded Quest for improved price strength, which can attract momentum and retail flows. IBD rating upgrades: Quest Diagnostics shows improved price strength
• Positive Sentiment: Zacks/style momentum coverage — Commentary suggesting DGX is a momentum stock may reinforce interest from style‑focused funds. Here’s Why Quest Diagnostics (DGX) is a Strong Momentum Stock
• Neutral Sentiment: Earnings call / deep dive pieces — Multiple writeups summarize the call and the shifting investment story (organic growth, consumer testing momentum, advanced diagnostics). Useful for longer‑term thesis but less likely to move the tape intraday. Quest Diagnostics Inc (DGX) Q1 2026 Earnings Call Highlights DGX Q1 deep dive
• Negative Sentiment: Hedge fund short call — Hedgeye added DGX as a new short idea, creating headline risk and giving short sellers a narrative to increase pressure in the near term. That can amplify intraday selling even with positive fundamentals. Quest Diagnostics added as new short idea at Hedgeye

Quest Diagnostics Trading Down 2.4%

Shares of DGX stock opened at $199.15 on Friday. Quest Diagnostics Incorporated has a 12-month low of $164.65 and a 12-month high of $213.50. The company has a market capitalization of $22.04 billion, a P/E ratio of 22.01, a P/E/G ratio of 2.61 and a beta of 0.66. The firm has a 50-day moving average price of $200.26 and a 200 day moving average price of $189.19. The company has a quick ratio of 0.96, a current ratio of 1.18 and a debt-to-equity ratio of 0.67.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings results on Tuesday, April 21st. The medical research company reported $2.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.37 by $0.13. Quest Diagnostics had a net margin of 9.07% and a return on equity of 15.60%. The firm had revenue of $2.90 billion during the quarter, compared to the consensus estimate of $2.83 billion. During the same period last year, the firm posted $1.94 EPS. The firm’s quarterly revenue was up 9.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. Research analysts forecast that Quest Diagnostics Incorporated will post 10.69 earnings per share for the current fiscal year.

Quest Diagnostics declared that its Board of Directors has initiated a stock repurchase plan on Tuesday, February 10th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 4.7% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s leadership believes its stock is undervalued.

Quest Diagnostics Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, April 20th. Investors of record on Monday, April 6th were issued a dividend of $0.86 per share. The ex-dividend date of this dividend was Monday, April 6th. This represents a $3.44 annualized dividend and a yield of 1.7%. This is an increase from Quest Diagnostics’s previous quarterly dividend of $0.80. Quest Diagnostics’s payout ratio is 38.01%.

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.